Transparência no setor farmacêutico: uma nova dimensão do debate internacional sobre acesso a medicamentos?

Competition Law and Access to Medicines: Lessons from Brazilian Regulation and Practice

“…This case acknowledges a key CADE competence, shared with other competition authorities and oversight bodies across the globe, i.e., the prerogative to demand information, including on innovation. As noted above, the lack of transparency is one of the main issues in the pharmaceutical sector, 43 allowing companies to overcharge and making it harder to fully understand the innovation, production and procurement processes.…”